University of New Mexico

UNM Digital Repository
Pediatrics Research and Scholarship

Pediatrics

5-1-2022

Protocol for the IMPACT Trial: Improving Healthcare Outcomes in
American Transplant Recipients Using Culturally-Tailored Novel
Technology
Claudia M. Rice
Pooja P Singh
Nila S. Judd
Elizabeth Yakes Jimenez
Cindy K. Blair

See next page for additional authors

Follow this and additional works at: https://digitalrepository.unm.edu/peds_pubs

Authors
Claudia M. Rice, Pooja P Singh, Nila S. Judd, Elizabeth Yakes Jimenez, Cindy K. Blair, Amy Washburn,
Christine Calvin, Alison Steiber, Yiliang Zhu, Christos Argyropoulos, Mark Unruh, Mary Amanda Dew, and
Larissa Myaskovsky

ORIGINAL RESEARCH

Protocol for the IMPACT Trial: Improving
Healthcare Outcomes in American
Transplant Recipients Using CulturallyTailored Novel Technology
Claudia M. Rice, BPH,* Pooja P. Singh, MD,† Nila S. Judd, BA,*
Dr. Elizabeth Yakes Jimenez, PhD, RDN,‡,§ Cindy K. Blair, PhD,{,** Amy Washburn, DPT,*,††
Christine Calvin, MS, RDN,*,‡‡ Dr. Alison Steiber, PhD, RDN,§ Yiliang Zhu, PhD,{
Christos Argyropoulos, MD, PhD,† Mark Unruh, MD, MPH,† Mary Amanda Dew, PhD,§§,{{,***,†††
and Larissa Myaskovsky, PhD*,†
Kidney transplant (KT) recipients face post-transplant health issues. Immunosuppressive agents can cause hyperlipidemia, hypertension, post-transplant diabetes, and glomerulopathy. Post-transplant weight gain and decreased activity are associated with poor quality
of life, sleep, and cardiometabolic outcomes. This study will test the feasibility and acceptability of a culturally tailored diet and exercise
intervention for KT patients delivered immediately post-transplant using novel technology. A registered dietitian nutritionist (RDN) and
physical rehabilitation therapist will examine participants’ cultural background, preferences, and health-related obstacles (with consultation from the transplant team) to create an individualized exercise and meal plan. The RDN will provide medical nutrition therapy via the
nutrition care process throughout the course of the intervention. The Twistle Patient Engagement Platform will be used to deliver and
collect survey data, communicate with participants, and promote retention. Outcomes to be assessed include intervention feasibility
and acceptability and intervention efficacy on patients’ adherence, medical, quality of life, and occupational outcomes.
Keywords: kidney transplant; post-transplant; lifestyle modification; diet and exercise; medical nutrition therapy
Ó 2022 by the National Kidney Foundation, Inc. All rights reserved.

Introduction

K

IDNEY TRANSPLANTATION (KT) is the treatment of choice for patients with kidney failure.1
Although KT reduces cardiovascular events, cardiacrelated death rates in KT recipients, remain up to 10 times
greater than in the general population.1-3 In some
cases, pretransplant cardiac risk factors may persist posttransplant, with KT recipients with diabetes-associated
kidney failure having higher mortality rates compared to
recipients with kidney failure due to other causes.4 Some
transplant-specific factors also increase cardiac risk.
Although they are necessary to decrease rejection,5
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post-transplant immunosuppressive agents are associated
with cardiometabolic complications (e.g., hyperlipidemia,
hypertension, post-transplant diabetes, and glomerulopathy).6-11 The most common approach to treating these
cardiometabolic complications is medication. However,
medication effectiveness varies,3,12,13 and patients may
find side effects unacceptable and face contraindications
with their complex, costly post-transplant immunosuppression regimen (e.g., calcium channel blockers, angiotensin
receptor
blockers,
ACE
inhibitors,
antihypertensive agents).6-10 Given the tremendous
resources that go into evaluating and transplanting kidney
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failure patients, it is important to explore effective, yet
potentially less costly approaches to reducing their cardiac
risk post-transplant.3
Weight gain in the first year after KT due to immunosuppressive drugs, existing comorbidities, and exercise
apprehension, contributes to elevated cardiometabolic
risk.14-18 In addition, low levels of physical activity and
reduced physical functioning are common after KT, and
are associated with a reduced quality of life (QOL)19 and
poor sleep quality.20 Reduced sleep quality can result in
mental and behavioral problems that further exacerbate
KT recipients cardiac risk factors.20 Behavioral counseling
focused on lifestyle modification (changes in diet and exercise) has been the mainstay for initial management of
obesity, diabetes, and cardiovascular disease for decades in
the general population.21-23 The US Preventive Service
Task Force recommends behavioral interventions
centered on nutrition and physical activity for adults at
risk for cardiovascular disease.21 In accordance with these
guidelines, an initial short-term investment in enhancing
lifestyle modification in KT recipients may yield longterm benefits and cost savings to patients and the healthcare
system. However, the presence of both traditional and
KT-specific risk factors for cardiovascular events and diabetes after transplantation,24-26 such as weight gain,
hypertension, deconditioning, and hyperlipidemia, makes
it critical to establish the feasibility and efficacy of an early
post-transplant lifestyle modification intervention specifically for the KT population.27-29 Although an approach
specifically tailored to KT recipients is an optimal
solution,30,31 seminal reviews of physical activity in the
KT population resulted in limited lifestyle management
guidelines for KT recipients.15,16 Additionally, a recent
evidence-based clinical practice guideline for nutrition
care in CKD and KT recipients from the National Kidney
Foundation and the Academy of Nutrition and Dietetics
found insufficient evidence to support several dietary recommendations specific to transplant recipients.32,33
Although a Cochrane review of dietary interventions for
CKD17 highlighted the limitations of current evidence of
dietary interventions, it only found 4 studies that included
a total of 168 KT recipients. Thus, interventions for KT patients are limited. It is also important to develop an intervention that accurately and appropriately reflects the
current KT population. The latest data from the Organ
Procurement and Transplantation Network shows that
racial and ethnic minorities comprise 46% of the KT population.34 However, a meta-analysis of lifestyle interventions35 found that only 10% were culturally appropriate
to the target population. We developed the current protocol to
address these gaps.
The Improving Healthcare Outcomes in American
Transplant Recipients Using Culturally Tailored Novel
Technology (IMPACT) pilot study is designed to test the
feasibility and acceptability of a culturally tailored,

multibehavior lifestyle intervention using a novel technology for KT recipients. This intervention will be the first of
its kind to work with KT patients immediately following
transplant. Because of KT recipients’ varied medical status
immediately post-transplant and the need to individually
monitor their post-transplant immunosuppression
regimen,2,12-14 a critical component of IMPACT is an
individually tailored exercise and diet plan with a physical
therapist/exercise physiologist (PT) and a registered
dietitian nutritionist (RDN), who will work closely with
the post-transplant team to carefully adjust the patient’s
plan to their medical needs. The IMPACT PT and RDN
will combine a personalized assessment of patient food
and exercise resources, barriers, and cultural and personal
preferences with consideration of clinical specifications
from the transplant team. This intervention is innovative
because it addresses previous limitations (small sample
size, limited follow-up, insufficient data collection),14-17
while adapting its components to meet the needs of the
culturally diverse kidney failure population. Although the
sample size for the pilot study is modest, it will amount
to approximately 12% of the sample in the Cochrane
group meta-analysis noted above and will serve as the foundation for our large-scale study. Another innovation of
IMPACT is the use of the Twistle Patient Engagement Platform by Health Catalyst36 to follow-up with participants
between their scheduled appointments, promote adherence to the intervention, collect all questionnaire data,
and enhance participant retention.
This paper describes the protocol of the IMPACT pilot
study. The study aims are to: (1) examine IMPACT’s
acceptability and feasibility in KT recipients; and (2)
explore the efficacy of IMPACT on proximal outcomes
(e.g., weight, lipid profile, HbA1c, sleep quality, QOL)
and distal outcomes (e.g., occupational functioning) in
KT recipients in line with SONG-Tx core outcomes.37
Please see Table 1 for an outline of aims, key outcome measures, and their operationalization. The findings of this pilot
study will be used to develop a large-scale, pragmatic clinical trial to test the efficacy and cost-effectiveness of
IMPACT on KT recipients’ post-transplant outcomes
(i.e., obesity, cardiovascular events, diabetes, sleep quality,
and QOL).

Methods
Overview
This pilot randomized clinical trial will assess the feasibility and acceptability of initiating a post-transplant diet
and exercise intervention for kidney transplant recipients
within 24-48 hours of receiving a transplant. KT patients
who received a transplant at a state-funded safety-net hospital with a kidney transplant center will be recruited for
this study. Also, to facilitate collaboration, the research
team will send a periodic email with concise descriptions
of the study purpose and procedures to the transplant

Downloaded for Anonymous User (n/a) at The University of New Mexico from ClinicalKey.com by Elsevier on June 28,
2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

IMPROVING HEALTH BEHAVIOR POST KIDNEY TRANSPLANT

e3

Table 1. Table of Aims and Outcome Measures
Aim

Outcomes

Aim 1: Examine IMPACT’s acceptability and feasibility in KT recipients
Acceptability
1a. Assess acceptability by patient ratings
of satisfaction with the culturally tailored
Feasibility
diet and exercise intervention,
as well as the Twistle patient engagement
platform.

Operationalization


Satisfaction with IMPACT Intervention
questionnaire
 Usability Scale for Twistle
 Usability scale for activPAL
 3-month brief satisfaction interview
 6-month in-depth satisfaction interview
1b. Assess feasibility by determining
Recruitment
 Eligible patients, number recruited,
recruitment and retention rates and
Retention
number retained
assessing participant
 Number refused, number withdrawn after
adherence to the IMPACT intervention
consent
 Study discontinuation tool and observation log to track reasons for refusal or
withdrawal
1c. Determine the ideal personnel hours
Visit frequency
 Visit frequency and duration with PT and
and the number of staff required for the
Visit duration
RDN including extra visits required to
physical therapist/exercise
help those patients with greater comorphysiologist and registered dietitian
bidities or acute events (infections or
nutritionist roles.
other reasons for hospitalization)
Aim 2: Test the efficacy of IMPACT on proximal outcomes (e.g., weight, lipid profile, HbA1c, sleep quality, QOL)
and distal outcomes (e.g., occupational functioning) in KTKT recipients
Adherence
 Diet and exercise adherence
2a. Assess participants’ adherence to the
questionnaire
exercise and diet intervention aspects of
IMPACT
 Nutrition follow-up visits
 PT follow-up visits
 ActivPAL Data – for physical activity
Quality of life, physical activity,
2b. Begin to examine changes in patient
 PROMIS QOL
sleep functioning, occupational
outcomes and the relationship between
 PROMIS Sleep-Related Impairment and
functioning, biochemical and
adherence to IMPACT
Sleep Disturbance Measures
anthropometric measures
and patient outcomes
 CHART-SF – occupational functioning
 EMR data

clinical and administrative staff. In addition to usual posttransplant care, intervention group participants will receive
a customized exercise and nutrition plan tailored by a PT
and an RDN. Periodic surveys assessing QOL, as well as
adherence to the diet and exercise plan, will be delivered using Twistle. Participants in usual care (UC) will only receive
standard post-transplant care, as well as periodic surveys.
Physical activity in all participants will be assessed using
the activPAL accelerometer and follow all participants for
12 months post-transplant. Finally, the study team will
conduct open-ended interviews with all intervention participants and clinic staff to assess their impressions and recommendations for the intervention. The study site’s
Human Research Protections Office (19-413) approved
the protocol.

Target Population
The research team will recruit 20 male or female kidney
transplant recipients. To be eligible for the study, patients
must be: 18 years of age or older, speak English, mentally
competent to make a voluntary decision about trial participation, and receive their kidney transplant from the study
site. A majority of kidney failure patients at the study site are
Hispanic/Latino/a (HL) (44%) or American Indian (AI)
(33%), have a household income of ,$25k, are on public

insurance, or have a high school or lower-level education.
Thus, the study sample will include disadvantaged populations that are underrepresented in past research and prepare
us to conduct a larger study in a diverse population.

Screening and Recruitment
All transplant physicians and transplant staff at the study
site will receive a twice-weekly email reminder regarding
the study inclusion and exclusion criteria and an inquiry
about any upcoming kidney transplants. Clinical team
members will notify the research team via email when
eligible patients are available for recruitment. The research
coordinator will approach eligible patients in the hospital
24-48 hours prior to or after transplant to review the consent form, address any questions, and obtain verbal and
written consent from the participant. Once patients consent to study participation, they will be randomized into
either the IMPACT intervention or UC study arms.
Random Assignment
Patients who consent to participate in the study will be
randomly assigned either to the IMPACT intervention or
the UC arm. Patients will be informed about the different
study arms during the consenting process. The research
team will not blind participants to their study condition,
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activPAL
Patient
Receives a
Transplant

Day 1

Month 1 (n=4):
1x/Week

Recruitment & random
assignment to IMPACT
or UC (pre-transplant)

Baseline
Interview for
everyone

IMPACT Group:
Intervention with
PT and RDN

activPAL

Month 2&3 (n=4):
2x/month

Month 4&5 (n=2):
1x/month

IMPACT Group:
Intervention with
PT (RDN – Month
3 only)

IMPACT Group:
Intervention with
PT only

activPAL

activPAL

Month 6 (n=1):
1x/month

Month 12:
Follow-up
Time

IMPACT Group: IMPACT Group:
Intervention with Intervention with
PT and RDN
PT and RDN

Figure 1. IMPACT and usual care participant pathway.

and participants will be given the option to switch conditions if they are not satisfied with their assignment. This option was included to assess intervention acceptability during
the pilot study; however, this option may be eliminated for
the larger-scale study to ensure proper randomization. The
study team will collect information about the number of
participants that chose to switch study assignments to
enhance information regarding intervention feasibility. A
blocked stratification randomization approach will be
used based on participant’s EMR-extracted racial and
ethnic group (non-Hispanic white, HL, non-Hispanic
AI/other race). Subsequent patients of each racial and
ethnic group will be alternately assigned to a study arm to
ensure equal distribution of intervention versus control in
each racial and ethnic group.

IMPACT Intervention and Adaptation
Participant burden will be minimized by scheduling
intervention visits (meetings with the PT and RDN) and
questionnaire assessments to commence during the hospital
stay and coincide with participants’ standard post-transplant
clinic visits (see Fig. 1). The transplant team schedules patients for appointments at the post-transplant clinic weekly
for the first month, then every 2 weeks for the next
2 months, then once a month at 4-6 months post-KT,
with a final visit at 12 months. Pairing intervention visits
with the post-transplant clinic appointments allow
IMPACT participants to have intensive support early on,
resulting in approximately 13 total visits over the course
of the first year post-transplant. Visit frequency will vary
depending on participants’ status and healthcare needs
post-transplant, with some participants requiring fewer or
more visits. Those in UC will not undergo any diet or exercise intervention but will wear an activity monitor at the
same assessment points as intervention participants (see
Section 2.5.2). The study team (including the PT and
RDN) will meet on a weekly basis to discuss each participant’s progress and to ensure that the PT and RDN intervention plans do not conflict.
Exercise Prescription and Structure
Pre-KTand post-KT patients report lower levels of physical activity than the general population due to fatigue, fear
of movement, and lack of clinician guidance.14 Due to heterogeneity among the exercise programs used in previous

post-KT studies, it is difficult to reach definitive conclusions regarding the benefit of aerobic versus resistance
training.14,16,27 Thus, for participants in the intervention
arm, the study will combine instruction that is professionally guided by a PT, and incorporates a rehabilitation
approach to slowly increasing KT recipients’ physical activity38-40 until they can engage in exercise at levels consistent
with the KDIGO guideline (i.e., exercise for 30 minutes, 5
times per week).41,42 This approach was taken because, in
the current era of personalized medicine, it would not be
appropriate to prescribe one form of exercise across all participants. A tailored approach to physical rehabilitation with
the end goal of a participant’s ability to meet the KDIGO
guidelines within their specific built environment is
optimal for patient health and outcomes. Participants in
the UC arm will not have any contact with our research PT.
Before hospital discharge, the study PTwill visit participants to conduct a structured assessment and begin a rehabilitation program. The PT will conduct a standardized
assessment of the participant’s history of physical activity using the Global Physical Activity Questionnaire (GPAQ).43
The PT will then discuss a list of goals with the participant
to determine what they would like to gain from the intervention. The domains of participant goals44 include relationships/family (e.g., participate in activities with
family), recreation/physical activity (e.g., increase social
life), employment/education (e.g., return to work), household care/maintenance (e.g., engage in care of family or
pets), and self-care (e.g., dress, bathe, and complete toileting independently). After determining participants’ goals,
the PT will assess participants’ functional mobility and
ambulation tolerance. The PTwill then prescribe an initial
walking program for the participant (e.g., walk 5 min, 33/
day), to be performed until the next PT visit.
At participants’ first outpatient clinic visit, the PT will
conduct assessments of their submaximal cardiovascular
endurance using the 6 Minute Walk Test (6MWT),45 functional strength using the 30-second chair stand test,46 and
static balance (i.e., feet together, semi-tandem, tandem,
and single-limb stance).47-49 The PT will also periodically
reassess these measures throughout the intervention to
determine participants’ functional progress. In addition,
during the clinic visits, the PT will prescribe and modify a
physical activity regimen. Physical activity will be focused
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on rehabilitation (i.e., walking, stationary cycling, and light
lower extremity strengthening and endurance exercises)
until the participant is surgically cleared for exercise
without restriction. Surgical clearance for lifting,
abdominal exercises, and activity that is more strenuous
generally occurs 6-8 weeks post-transplant, at which point
the PT will guide participants to increase the intensity and
variety of their exercise program. The PTwill assess participants’ tolerance to the intervention by their self-reported
subjective comments and the Borg Rate of Perceived Exertion Category-Ratio Scale.50
The PT may meet with an intervention participant a total of 13 times throughout the study because protocol visits
will coincide with their other post-transplant visits. However, their visit frequency with the PT may vary depending
on their post-transplant clinic visit schedule, which will
depend on a specific participant’s post-transplant functional
status as assessed by the transplant team. The first 2 PT visits
will be in-person to conduct assessments and set goals. If the
study PT is unable to see a participant at their prescheduled
visit, the PT will conduct subsequent visits over Zoom or
telephone to reduce participant burden. Throughout the
intervention, the PT will prescribe a combination of aerobic and resistance exercises relating to lower extremity
strengthening (e.g., heel raises, lunges, standing hip extensions), upper extremity strengthening (e.g., bicep curls,
pushups, rows), core strengthening (e.g., planks, inchworms), balance exercises (e.g., tandem stance, sidestepping), general flexibility (e.g., hamstring stretch, biceps
stretch), and cardiovascular exercises (e.g., walking, cycling,
jumping jacks). The PTwill gradually incorporate and periodically adjust these exercises at subsequent visits to best
address the participant’s goals and needs.
Physical Activity Monitoring
Within 1 week post-transplant, the study team will assess
a ‘‘baseline’’ test of physical activity, including a measure of
time spent sedentary (i.e., sitting/lying), standing, and stepping (and the intensity) during awake hours using the activPAL accelerometer.51,52 The activPAL is an electronic
activity monitor - a small, thin device, similar to a patch,
which can be worn on a participant’s mid-thigh during
the day and overnight. Regardless of condition, all study
participants will wear the device for 1 week, 4 times
throughout the duration of the study (see Fig. 1): 47 days post-transplant, 6-8 weeks post-transplant, and
then at 6- and 12-month post-transplant. Participants will
be instructed to mail back the activPAL monitor using a
preaddressed envelope after each use.
Diet Prescription and Structure
As in most other transplant centers, post-transplant usual
care in our center includes 1 post-transplant visit with an
RDN. Patients only see an RDN again if they have a newly
identified condition requiring nutrition counseling, such as
uncontrolled or new-onset diabetes, or require a
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post-transplant diet clarification. In contrast, KT recipients
in our IMPACT trial will see the RDN interventionist
once per week during the first month of the intervention
and then once at 3, 6, and 12 months post-transplant.
Based on nutrition care guidelines from KDOQI and
other national and international sources32,53, the first nutrition visit will occur immediately post-transplant, before patients are discharged from the hospital, to emphasize the
importance of nutrition in the midst of the intensive medical intervention and management. During this meeting,
the RDN will assess participants’ cultural background,
food preferences and habits, functional abilities and health,
nutrition risks, and food security using an adapted version
of the Home and Community Care food service client cultural
food preferences assessment tool.54 At future meetings between
the RDN and participants, the RDN will provide medical
nutrition therapy via the nutrition care process (NCP), as
described by the Academy of Nutrition and Dietetics.55
The NCP involves conducting a comprehensive nutrition
assessment, which includes reviewing participants’ food
and nutrition-related history (e.g., meal patterns, food
habits), as well as assessing nutrition-focused physical findings (e.g., appetite, chewing problems, swallowing problems, gastrointestinal problems). The RDN will make a
nutrition diagnosis, work with participants to identify
appropriate nutrition intervention(s) and goals and establish
a nutrition prescription, monitor and evaluate progress on
the goal and set new goals as appropriate at subsequent sessions. Example nutrition interventions that will be facilitated by the RDN include individualized nutrition
education, counseling (e.g., cognitive behavioral therapy
and motivational interviewing techniques), skill-building
support related to food purchasing and preparation and
diet self-monitoring, coordination of care (e.g., referrals
to community resources to assist with food security), and
overcoming nutrition barriers (e.g., post-transplant dietary
knowledge deficit, management of gastrointestinal problems).53 Dietary prescriptions will consider participants’
history, knowledge, beliefs, and preferences. The RDN
will conduct visits in either in-clinic, or over Zoom, or
over the telephone, depending on participant availability
and document care into REDCap56 using standardized
Nutrition Care Process Terminology.55 Although the
RDN will use the NCP to assess participants’ dietary preferences, needs, and goals, these visits will also serve as a tool
for providing dietary prescriptions based on participants’
history, knowledge, beliefs, and preferences. During these
follow-up visits, the RDN will also monitor changes in participants’ dietary intake, anthropometric measures (e.g.,
body mass index [BMI]), and biochemical values (i.e., electrolytes, glucose, A1c, HDL, LDL, and triglycerides). The
continued support participants receive from an RDN at the
follow-up visits will support achievement and maintenance
of dietary patterns that meet their individualized nutritional
needs post-transplant while also helping to establish
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nutrition behaviors that reduce the risk of excess weight
gain and elevated cardiometabolic risk.
The Twistle Patient Engagement Platform by
Health Catalyst
The most critical innovation of the IMPACT study is the
use of the Twistle patient engagement platform.36 Twistle is
a HIPAA-compliant patient engagement platform designed
to perform across all clinical specialties, procedures, and
chronic conditions. Because Twistle is a multimodal platform, it can deliver messages and reminders through smartphone apps (Apple and Android), text message (SMS),
computer browsers, EHR portal, and regular landlines using interactive voice response (IVR) or recorded voice.
Twistle allows participants to receive messages regardless
of geographic location, addressing concerns regarding
internet and provider access in rural communities.57,58
The research team will use Twistle to create and deploy
the periodic questionnaires and to send personalized reminders and check in with participants to assess adherence
to the intervention and promote maintenance of behaviors
(see Section 2.6 Data Collection, for specific measures and
timelines). The application allows confirmation of message
delivery, participant engagement with the surveys (when a
participant views a message versus when they complete a
survey, time to survey completion), and triage alert monitoring (automated reminders about surveys and activPALs
sent to participants and study staff). Study staff will call participants without smartphones to complete surveys but will
use Twistle to track survey deployment and capture questionnaire data. All participant communication through
Twistle is automated (i.e., survey deployment, survey reminders); however, study staff can directly communicate
with participants through Twistle in real time, if needed.

Data Collection
Table 2 lists59 all60 study61 assessments62 and63 frequency64. The65 primary66 endpoints67 for68 the69 pilot70
trial are intervention acceptability and feasibility. The study
team will monitor and review study progress on a weekly
basis.
Outcome Variables
Intervention acceptability will be assessed with participants’ satisfaction with the intervention using a revised
version of the Client Satisfaction Questionnaire,63 where
higher satisfaction will indicate greater intervention
acceptability, and the System Usability Scale (SUS),65
where higher scores indicate ease of usability of the Twistle
system. ActivPAL usability and practicality will be assessed
with the 11-item activPAL user-friendliness questionnaire.64 Questionnaire acceptability will be assessed using
open-ended participant questions. The study team will
keep a detailed log of relevant factors that could create barriers to subsequent study completion to provide concrete

estimates of the expected rates of missing data and
participant attrition.
ActivPAL accelerometers will be used to measure participants’ time spent sedentary (sitting/lying), standing, and
stepping (and the intensity) during awake hours, and these
values will be compared between the IMPACT and UC
groups. Additionally, the feasibility and acceptability of
the diet and exercise intervention components will be assessed. The study team will analyze the PT and RDN participants’ visit documentation and assessments to examine
visit attendance and identify patterns in diet and exercise
care (e.g. type and duration of exercise prescribed, common nutrition diagnoses, and interventions). The study
will also use visit documentation to determine key elements
of the PT and RDN care and identify practices to standardize for a larger, multisite trial. Survey completion
times, as well as intervention session time estimates, will
provide data regarding the time required for study
participation.
Also, the study team will assess the feasibility and acceptability of collecting a number of key participant outcomes
in line with SONG-Tx core outcomes14-16,18,27: (1) clinical data from participants’ medical records, including
weight, lipid profile, HbA1c, BMI, glucose, and medications; and (2) patient-reported outcomes,32,60,71 including
the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 Global Health Measure,
and the PROMIS Sleep-Related Impairment and Sleep Disturbance Measures.60 PROMIS measures are brief, based on
extensive item banks, have been validated in general and
kidney disease populations,72,73 and are favored by the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.66 Occupational
functioning (ability to perform activities of daily living)
will be assessed using the occupation subscale of the
CHART-SF.74 The CHART-SF is the most widely used
participation measure in rehabilitation research and has
been validated with various race/ethnic groups.75
Demographic and Health Predictors
The research team will collect demographic information, health predictors, and other covariates from participants. These items include gender, age, race and
ethnicity,59 marital status, education, occupation, income,
and insurance status. The study team will abstract pretransplant health variables (i.e., dialysis duration, BMI, number
of pretransplant hospitalizations, frailty, medical comorbidities using the Charlson Co-Morbidity Index,70 and indication for KT) from participants’ medical records.70
Participants’ level of fear of pain due to movement will be
assessed with the Tampa Scale for Kinesiophobia.62 Participants’ evaluation of their available social support will be assessed using the PROMIS Short Form v2.0 item bank.60
The 7-item Sense of Mastery scale61 will be used to assess
the degree to which participants feel they have personal
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Session Frequency
Variable Name
Predictors
Culturally-tailored diet and exercise baseline assessment
Food Assessment Questionnaire54
GPAQ Questionnaire43
Demographics59
Social Support questionnaire60
Mastery scale61
Kinesiophobia questionnaire62
Outcomes
QOL questionnaire60
Sleep Quality questionnaire60

Baseline

Month 2
Bi-weekly

Month 3
Bi-weekly

Month 4 & 5
Monthly

Month 6
Once

Month 12
Once

Intervention
Intervention
All
All
All
All
All
All

Satisfaction with IMPACT intervention scale63
Usability scale for activPAL64
Usability scale for Twistle65
Occupational functioning questionnaire66
Diet and exercise adherence questionnaire67
activPAL Data Collection51,52
In-depth interview68,69
EMR data abstraction59,70

Month 1
Weekly

Intervention
(week 4 only)
Intervention
(week 4 only)

Intervention
(end of Month 3)
Intervention
(end of Month 3)
Intervention

Intervention
(week 4 only)
All
Intervention
All (prerehab)

Intervention

Intervention
All (post-rehab)
Intervention

Intervention

All

All

All

All

Intervention

Intervention
Intervention
Intervention

All
Intervention
All
Intervention

All
Intervention
All
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control over the things that happen to them. The study
team will measure adherence to the diet and exercise plan
with a modified version of our post-transplant adherence
questionnaire.67,68 The primary goal for this study is to
assess the feasibility of collecting this data rather than
measuring any changes in these measures.

research, clinical, and administrative teams. The survey
data will be quantitatively analyzed, categorizing comments
as to which of the major CFIR domains (Intervention,
Outer Setting, Inner Setting, Characteristics of Individuals,
Process) they refer and assessing counts and frequencies of
comments found in each construct.

Intervention Evaluation
The research team will evaluate the process of
implementing the IMPACT intervention using a mixedmethods approach consistent with a Type I Hybrid Intervention/Implementation design.69 Using the Consolidated
Framework for Implementation Research (CFIR)76 as a
theoretical framework, we will assess barriers and facilitators to implementation to provide real-time feedback for
the pilot and to inform the future large-scale project.
This evaluation will comprise a periodic survey with clinical (i.e., PT, RDN) and administrative staff regarding barriers and facilitators of implementation, as well as in-depth
interviews with intervention group participants. Given that
this is a multicomponent intervention, the survey and indepth interview approach to intervention evaluation will
allow the study team to disentangle staff and participant
perceptions of the feasibility and effectiveness of the various
components for the participants: individualized prescription of culturally tailored physical activity and diet plan
and the Twistle platform.
Patient satisfaction questionnaire and indepth interviews. A brief questionnaire will be
used to survey intervention participants at 3 months posttransplant about their satisfaction with the study. At
6 months, in-depth, open-ended interviews will be conducted with intervention participants to further assess study
satisfaction, and examine their approval of the intervention
with a focus on their overall experience and recommendations for improvement. All interviews will be recorded and
transcribed.
Staff surveys. Clinical and administrative staff will
be contacted periodically to provide intervention feedback.
Staff surveys include their assessment about barriers or facilitators to the intervention they observed or experienced,
and suggestions for change if indicated. Observed barriers
and facilitators can be related to direct staff activities or observations of participants interacting with study staff members. We will elicit feedback from the transplant team on the
intervention process. We will ask for impressions of the
IMPACT intervention and solicit suggestions regarding
optimizing the future large-scale study.
Internal evaluation. The research coordinator
will document all observations and experiences in a Study
Observation Log, noting the date and source of the observation. The study team will review the log during research
team weekly meetings and identify any process change
needs. The research team will then iteratively communicate
the problems identified and planned changes to the

Participant Reimbursement and Retention
Methods
Participants will be reimbursed for their study participation in $20.00 increments. Participants in the IMPACT
intervention arm will receive payments each time they
complete a series of questionnaires through Twistle. Those
in the intervention group will also receive an additional
$20.00 payment after completing an in-depth interview
with study staff at 6 months. Participants in the UC arm
will receive payments for completing baseline, 6 months,
and 12 months surveys. Thus, intervention participants
can receive up to 13 payments maximum ($260.00) for
participating in the study in its entirety, and UC participants
can receive up to 3 payments ($60.00) for study participation. To facilitate retention and encourage open communication, intervention participants will have frequent contact
with the study team via PT and RDN visits and the Twistle
patient engagement platform. Participant retention efforts
will be documented using Excel and REDCap,56,77 and assessed during weekly study team meetings. These meetings
will include a discussion of reasons for patient refusal and
offer opportunities to discuss strategies to improve recruitment and retention rates.

Analysis of Specific Aims
Primary and Ancillary Analysis
The participant sample will be analyzed with detailed
descriptive statistics regarding demographics and healthrelated characteristics. Missing data points during the study,
including attrition and its underlying reasons, will be recorded and summarized as well. The primary analysis will
focus on measures of feasibility and acceptability as outlined
in Aim 1: Examine IMPACT’s acceptability and feasibility
in KTrecipients (see Table 1). These analyses will be used to
determine endpoints, their variation, plausible intervention
effect size, sample size, planned analyses, and accrual expectations. These analyses will guide the design of the subsequent study.78 Also, these analyses, along with those of
Aim 2, will be used to determine a clear rationale to support
the next steps in the study process, including ‘‘go versus no
go’’ decisions.78
For Aim 2, ‘‘Test the efficacy of IMPACT on proximal
outcomes (e.g., weight, lipid profile, HbA1c, sleep quality,
QOL) and distal outcomes (e.g., occupational functioning)
in KT recipients,’’ we will explore the intervention effects
on adherence to the diet and exercise intervention, and
compare proximal and distal outcomes between groups.
This analysis will compare the intervention and UC group

Downloaded for Anonymous User (n/a) at The University of New Mexico from ClinicalKey.com by Elsevier on June 28,
2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

IMPROVING HEALTH BEHAVIOR POST KIDNEY TRANSPLANT

on type, frequency, and intensity of exercise, as well as
changes in weight and laboratory values, sleep quality,
occupational functioning, and QOL using descriptive statistics and nonparametric methods. The activity in both
groups will be compared using the activPAL data. For
example, this analysis will answer the questions: what is
the plausible range of difference in the proportion of participants engaging in the recommended diet and exercise
routine and experiencing positive changes in proximal
and distal outcomes? What is the difference in the amount
of activity between the 2 groups? Given the small sample
size of this study, we do not expect such differences will
be statistically significant, but such differences will inform
the planned large-scale study. In addition, analyses will
consider participants’ diet and exercise adherence in relation to proximal outcomes, such as weight and lipid profile.

Qualitative Data Analysis
The core research team will review all of the interview
transcripts to develop an annotated provisional codebook,
using qualitative analysis software (Dedoose)79 to support
this analysis. The subsequent interviews will be iteratively
analyzed as follows: 2 primary coders will apply existing codes and will add new codes to the codebook as needed.
Disagreement in coding will be resolved through
consensus, and inter-rater agreement between coders will
be assessed.80 The study team will maintain an audit trail
to track coding decisions, and we will use memos
throughout the analysis to identify key emerging concepts.
Thematic analysis will be conducted to identify key concepts, including confirmation of existing knowledge and
identification of novel themes.
The study team will create a provisional codebook with
the barriers and facilitators identified in the brief surveys
with clinical team members. Particular attention will be
paid to themes that deal with the overall ease of use of the
intervention and overall satisfaction with implementation.
The study team will map the results of the qualitative analysis to the major CFIR domains.
Sample Size Estimates
Although power estimates are not necessary for a pilot
feasibility study, we used data from the last 5 years of KT recipients at the transplant center to estimate the number of
patients we can expect to recruit for the study. The center
transplants more than 40 patients per year. Of all eligible patients who receive a KT, we expect that 80% will agree to
participate in our study, based on previous intervention
research with KT patients,8,18,28,29,39,81 and our own
work.82,83 Due to the number of patients transplanted at
the transplant center annually, a reasonable recruitment
target of 20 KT recipients was set for the pilot study.

Discussion
KT recipients encounter elevated cardiometabolic risks
post-transplant.2,3 This risk is due to the increased
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likelihood of transplant recipients experiencing weight
gain, hyperlipidemia, hypertension, and developing
post-transplant diabetes in the first year after
transplant.6-11,28,29 These conditions result in higher mortality rates4 and reduced QOL19 for transplant recipients.
The IMPACT trial will address this urgent clinical demand
in KT by assessing an intervention that may reduce the likelihood of weight gain, uncontrolled diabetes, new-onset
diabetes, and cardiovascular events in patients posttransplant. This trial will also address the need to culturally
tailor and individualize lifestyle interventions35 using careful assessment and consideration when prescribing diet and
exercise regimens. By providing KT recipients with an
intensive, personalized nutrition and exercise regimen
that acknowledges and addresses structural barriers and integrates their cultural and other preferences, intervention
participants will have the support, knowledge, resources,
and self-efficacy to adhere to the program and improve
their post-transplant health. Intervention adherence will
be promoted through recurrent follow-up by the PT and
RDN and the use of Twistle, which will serve as a means
to remain in frequent contact with participants. Collecting
detailed information on the PTand RDN intervention and
using the Twistle patient engagement platform will provide
the means to easily standardize, package, and disseminate
the intervention to other transplant centers.
A major strength of this pilot trial is that it is being conducted with a transplant center that serves a high proportion of HL and AI patients, who are traditionally
underrepresented in KT research and who may experience
poorer KToutcomes because of limited resources and infrastructure to address structural barriers and to individualize
interventions during usual care. It is essential that a larger
trial includes underserved KT patients. Thus, feasibility
and acceptability information from this pilot trial will
help to ensure that this goal is a possibility. Although the
small sample size of this study may not allow conclusions
on participants’ clinical outcomes, the study will collect
descriptive data about weight improvements, changes to
lipid panels, and physiological benefits of exercise and
diet in kidney transplant recipients. This pilot study will
provide invaluable information for the development of a
large-scale intervention study. The large-scale trial will be
the first to examine early post-transplant behavioral interventions and will establish a foundation for other transplant
centers to implement custom healthy lifestyle interventions
for KT recipients. Future research from this study team will
examine cost-effectiveness, insurance reimbursement for
allied health provider intervention costs, and translation
of study materials to other languages.

Practical Application
Given the tremendous resources that go into evaluating
and transplanting kidney failure patients, it is important to
explore effective, yet less costly approaches to reducing
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post-transplant health risks. This intervention is a multimodal health-system pragmatic clinical intervention designed to improve the health behavior of kidney
transplant recipients immediately post-transplant. The
research team will use the findings from this pilot trial to
develop a large-scale, pragmatic clinical trial to test the efficacy and cost-effectiveness of the intervention on kidney
transplant recipients’ post-transplant outcomes in the 3
largest minority racial/ethnic kidney failure groups: Black
Americans, Hispanics, and American Indians.
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